A guide to prescribing home phototherapy for patients with psoriasis: The appropriate patient, the type of unit, the treatment regimen, and the potential obstacles - 17/04/15
, Steven R. Feldman, MD, PhD a, b, cAbstract |
Background |
Ultraviolet B phototherapy is underused because of costs and inconvenience. Home phototherapy may alleviate these issues, but training is spotty, and many physicians are not comfortable prescribing home phototherapy.
Objective |
The purpose of this review is to provide a practical guide for recognizing appropriate patients, prescribing, and dealing with potential obstacles for home phototherapy treatment.
Methods |
Current guidelines for treatment of psoriasis were used to describe an appropriate patient for home phototherapy. Current literature and resources from phototherapy providers were reviewed to determine appropriate type of light, unit, treatment regimen, and how to navigate the insurance claim process.
Results |
Treatment schedules vary based on skin type. Home phototherapy companies provide various units suited for individual situations. Assistance can be used from suppliers to facilitate the process of obtaining a home phototherapy unit and navigating obstacles.
Limitations |
Phototherapy treatment varies on an individual basis, so this review serves only as a guide.
Conclusion |
Home phototherapy is a suitable treatment for many patients for whom office-based phototherapy is not accessible. Home phototherapy companies simplify the process by providing assistance for prescribing home light units.
Le texte complet de cet article est disponible en PDF.Key words : broadband ultraviolet B, home phototherapy, insurance, narrowband ultraviolet B, phototherapy, psoriasis, ultraviolet A
Abbreviations used : MED, NB, UV
Plan
| The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories LP. |
|
| Disclosure: Dr Feldman is a speaker for Janssen and Taro. He is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, Leo Pharma Inc, and Novartis. He has received grants from Galderma, Janssen, Abbott Labs, Amgen, Stiefel/GlaxoSmithKline, Celgene, and Anacor. He is a consultant for Amgen, Baxter, Caremark, Gerson Lehrman Group, Guidepoint Global, Hanall Pharmaceutical Co Ltd, Kikaku, Lilly, Merck & Co Inc, Merz Pharmaceuticals, Mylan, Novartis Pharmaceuticals, Pfizer Inc, Qurient, Suncare Research, and Xenoport. He is on an advisory board for Pfizer Inc, Abbvie, and Celgene. He is the founder and holds stock in Causa Research and holds stock and is majority owner in Medical Quality Enhancement Corp. He receives Royalties from UpToDate and Xlibris. Ms Anderson has no conflicts of interest to declare. |
Vol 72 - N° 5
P. 868 - mai 2015 Retour au numéro
Article précédent
- Cutaneous manifestations of pediatric granulomatosis with polyangiitis: A clinicopathologic and immunopathologic analysis
- Adam C. Wright, Lawrence E. Gibson, Dawn Marie R. Davis
- Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology
- Alexander L. Fogel, Sharleen Hill, Joyce M.C. Teng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?